ClinicaliQ Trial Snapshot
- A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) — Recruiting • Phase III • Oncology • NCT07099898.
- Drug being tested: GSK5764227 (Risvutatug rezetecan/Ris-Rez) is a novel B7-H3-targeted therapy designed to inhibit cancer cell growth and metastasis in patients with relapsed small cell lung cancer (SCLC).
- Patient eligibility overview: This trial enrolls patients with relapsed SCLC who have progressed despite prior treatment, representing a population with limited therapeutic options and poor prognosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding…
Eligibility Snapshot
- : Participants are eligible to be included in the study only if all of the following criteria apply: * Adults >18 or the minimum legal adult age at the time the informed consent form is signed * Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). * Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor for at least 2 cycles of therapy and a chemotherapy free-interval of >30 days, with documented progression. Participants with prior tarlatamab treatment in either the first- or second-line ES-SCLC setting are eligible. * Has at least 1 target lesion per RECIST 1.1, as determined by the investigator. * Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Has adequate organ function and an ECOG performance status of 0 or 1
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.